People: Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

56.40USD
21 Nov 2014
Price Change (% chg)

$1.15 (+2.09%)
Prev Close
$55.24
Open
$55.62
Day's High
$56.42
Day's Low
$55.44
Volume
689,358
Avg. Vol
865,904
52-wk High
$56.42
52-wk Low
$37.29

Search Stocks

Dixon, Wendy 

Brief Biography

Dr. Wendy L. Dixon Ph.D. is an Independent Director of Alkermes Plc. From January 2011 to September 16, 2011, Dr. Dixon served on the Alkermes, Inc. board of directors. She has extensive experience in the pharmaceutical and biotechnology industries, combining a technical background with experience in drug development, regulatory affairs and marketing. She directed the launches and growth of more than 20 pharmaceutical products. From 2001 to 2009 she was Chief Marketing Officer and President, Global Marketing for Bristol-Myers Squibb where she served on the Executive Committee. From 1996 to 2001 she was Senior Vice President, Marketing at Merck, and prior to that, she held executive management positions at West Pharmaceuticals, Osteotech and Centocor and various positions at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon is on the board of directors of Furiex Pharmaceuticals, Orexigen Therapeutics, Incyte Corporation, and bluebird bio, all publicly traded biotechnology or pharmaceutical companies, and was formerly on the board of Dentsply International. In addition, she is on the board of directors at, Edimer Pharmaceuticals, a privately held pharmaceutical company.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops

8,696,650

Shane Cooke

3,912,100

James Frates

2,095,130

Gordon Pugh

1,965,720

Kathryn Biberstein

2,488,720

Rebecca Peterson

--
As Of 30 Mar 2014
Search Stocks